Zurich Cantonal Bank’s Travere Therapeutics TVTX Stock Holding History

Zurich Cantonal Bank’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12M	Buy	37,560 +6,683	+22%	+$200K	﹤0.01%	1367
2025 Q4	$1.18M	Buy	30,877 +5,344	+21%	+$174K	﹤0.01%	1252
2025 Q3	$610K	Sell	25,533 -195	-0.8%	-$3.67K	﹤0.01%	1626
2025 Q2	$381K	Buy	25,728 +2,772	+12%	+$45.9K	﹤0.01%	1820
2025 Q1	$411K	Buy	22,956 +2,987	+15%	+$60.6K	﹤0.01%	1713
2024 Q4	$348K	Hold	19,969	–	–	﹤0.01%	1846
2024 Q3	$279K	Buy	19,969 +3,458	+21%	+$36K	﹤0.01%	1921
2024 Q2	$136K	Hold	16,511	–	–	﹤0.01%	2238
2024 Q1	$127K	Hold	16,511	–	–	﹤0.01%	2276
2023 Q4	$148K	Hold	16,511	–	–	﹤0.01%	2248
2023 Q3	$148K	Buy	16,511 +4,007	+32%	+$56.5K	﹤0.01%	2156
2023 Q2	$192K	Buy	12,504 +193	+2%	+$3.51K	﹤0.01%	1949
2023 Q1	$277K	Buy	12,311 +2,879	+31%	+$61.2K	﹤0.01%	1674
2022 Q4	$198K	Buy	9,432 +1,928	+26%	+$40.9K	﹤0.01%	1823
2022 Q3	$185K	Hold	7,504	–	–	﹤0.01%	1806
2022 Q2	$182K	Sell	7,504 -2,169	-22%	-$54.5K	﹤0.01%	1853
2022 Q1	$249K	Sell	9,673 -1,013	-9%	-$26.9K	﹤0.01%	1756
2021 Q4	$332K	Buy	10,686 +3,006	+39%	+$84.7K	﹤0.01%	1744
2021 Q3	$186K	Buy	7,680 +4	+0.1%	+$73	﹤0.01%	1975
2021 Q2	$112K	Buy	7,676 +89	+1%	+$1.75K	﹤0.01%	2160
2021 Q1	$189K	Sell	7,587 -147	-2%	-$4.06K	﹤0.01%	1812
2020 Q4	$211K	Hold	7,734	–	–	﹤0.01%	1811
2020 Q3	$143K	Hold	7,734	–	–	﹤0.01%	1817
2020 Q2	$158K	Buy	7,734 +5,564	+256%	+$88.6K	﹤0.01%	1677
2020 Q1	$32K	Hold	2,170	–	–	﹤0.01%	2153
2019 Q4	$31K	Hold	2,170	–	–	﹤0.01%	2370
2019 Q3	$25K	Hold	2,170	–	–	﹤0.01%	2387
2019 Q2	$44K	Hold	2,170	–	–	﹤0.01%	2141
2019 Q1	$49K	Sell	2,170 -668	-24%	-$14.8K	﹤0.01%	2022
2018 Q4	$64K	Hold	2,838	–	–	﹤0.01%	1882
2018 Q3	$82K	Hold	2,838	–	–	﹤0.01%	1846
2018 Q2	$77K	Hold	2,838	–	–	﹤0.01%	1827
2018 Q1	$63K	Hold	2,838	–	–	﹤0.01%	1901
2017 Q4	$60K	Buy	2,838 +966	+52%	+$22.1K	﹤0.01%	1918
2017 Q3	$47K	Hold	1,872	–	–	﹤0.01%	1846
2017 Q2	$36K	Hold	1,872	–	–	﹤0.01%	1956
2017 Q1	$35K	Hold	1,872	–	–	﹤0.01%	2003
2016 Q4	$35K	Buy	1,872 +239	+15%	+$4.89K	﹤0.01%	1952
2016 Q3	$37K	Hold	1,633	–	–	﹤0.01%	1842
2016 Q2	$29K	Hold	1,633	–	–	﹤0.01%	1829
2016 Q1	$22K	Hold	1,633	–	–	﹤0.01%	1976
2015 Q4	$32K	Buy	1,633 +1,309	+404%	+$26.1K	﹤0.01%	1734
2015 Q3	$7K	Buy	+324	New	+$9.6K	﹤0.01%	2302

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zurich Cantonal Bank's TVTX Position: Q1 2026 in Review

Zurich Cantonal Bank increased its Travere Therapeutics (TVTX) stake by 22% in Q1 2026, buying an estimated $200K and bringing the position to 37,560 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Zurich Cantonal Bank first reported a position in TVTX in Q3 2015 and has held it in 43 quarters since. The position peaked at $1.18M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Zurich Cantonal Bank held 37,560 shares of Travere Therapeutics worth $1.12M as of Q1 2026.
Zurich Cantonal Bank bought 6,683 Travere Therapeutics shares in Q1 2026, an estimated $200K.
Travere Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1367 holding.
Zurich Cantonal Bank first reported a position in Travere Therapeutics in Q3 2015 and has held it in 43 quarters since.
Zurich Cantonal Bank's Travere Therapeutics position peaked at $1.18M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.